Spirulina and Pancreatic Cancer: The First Human Clinical Trial + Latest Research (2026)

Medically Reviewed Content | Last Updated: March 30, 2026 | Author: Royal Spirulina Research Team

Pancreatic cancer is one of the deadliest cancers in the world, with a five-year survival rate below 13%. Standard chemotherapy options remain limited, and the disease is notoriously resistant to treatment. That’s what makes the emerging research on spirulina and pancreatic cancer so compelling.

In a Phase I clinical trial at Shanghai General Hospital, a spirulina-derived oral drug called K-001 achieved an 83.3% disease control rate in patients with advanced pancreatic ductal adenocarcinoma (PDAC) — with zero grade 3 or 4 adverse events. Meanwhile, laboratory research has shown that phycocyanin — spirulina’s signature blue pigment — directly kills pancreatic cancer cells through multiple molecular pathways, while a brand-new 2026 study identified a spirulina polysaccharide that inhibits PDAC growth by targeting galectin-3.

This article reviews the complete body of research on spirulina and pancreatic cancer — from the groundbreaking human clinical trial to the latest preclinical studies — so you can understand what the science actually shows.

---

The First Human Clinical Trial: K-001 in Advanced Pancreatic Cancer

The most significant piece of evidence for spirulina and pancreatic cancer is a Phase I clinical trial conducted at Shanghai General Hospital (Shanghai Jiao Tong University School of Medicine) and published in BMC Cancer in 2021. This trial tested K-001 — an oral antitumor drug made from active ingredients of marine microorganisms, specifically derived from spirulina — in patients with advanced pancreatic ductal adenocarcinoma (PDAC).

Study Design

The trial was an open-label, dose-escalation study using the standard 3+3 design. Eighteen patients with advanced PDAC were screened, and twelve eligible patients were enrolled. All had either failed standard treatment or were not suitable for conventional chemotherapy. K-001 was administered orally twice daily in four-week cycles at escalating doses:

• Group A: 2,700 mg/day (1,350 mg twice daily)
• Group B: 3,240 mg/day (1,620 mg twice daily)
• Group C: 3,780 mg/day (1,890 mg twice daily)
• Group D: 4,320 mg/day (2,160 mg twice daily)

Safety Results

The safety profile was remarkable for a cancer drug trial:

• No dose-limiting toxicity (DLT) was observed at any dose level
• No grade 3 or grade 4 drug-related adverse events
• 14 drug-related adverse events were reported in 7 patients: 8 were grade 1 (57.1%) and 6 were grade 2 (42.9%)
• The most common side effects were mild digestive issues: dyspepsia (21.4%), flatulence, constipation, and hemorrhoid bleeding
• The maximum tolerated dose was not reached — even the highest dose (4,320 mg/day) was well tolerated

Efficacy Results

For a Phase I trial (which primarily evaluates safety), the efficacy signals were striking:

• 10 of 12 patients (83.3%) achieved stable disease (SD) — meaning their cancer stopped progressing
• Only 2 patients (16.7%) had progressive disease
• Disease control rate (DCR): 83.3%
• The study also measured secondary endpoints including quality of life (EORTC QLQ-C30), pain scores (NRS), regulatory T cell counts, and C-reactive protein levels

Why This Matters

An 83.3% disease control rate in advanced PDAC — in patients who had already failed standard treatment — is a meaningful signal. Pancreatic cancer is notorious for its resistance to therapy, and most patients with advanced disease have limited options. The fact that K-001 achieved this with essentially no serious toxicity makes it particularly noteworthy.

The researchers concluded that K-001 “manifests satisfactory safety and tolerability, as well as meaningful antitumor activity in advanced PDAC patients” and recommended further Phase II/III evaluation.

Reference: Cui et al., BMC Cancer, 2021. ClinicalTrials.gov: NCT02720666.

---

Phycocyanin Kills Pancreatic Cancer Cells: The Laboratory Evidence

The clinical trial above tested a formulated spirulina-derived drug, but what about phycocyanin itself? A landmark 2016 study published in Scientific Reports (Nature) provided the most comprehensive evidence that phycocyanin has direct anti-pancreatic cancer activity.

In Vitro Results (Cell Studies)

Researchers at China Pharmaceutical University tested phycocyanin against PANC-1 cells — one of the most widely used human pancreatic cancer cell lines. The results were clear:

• Dose-dependent growth inhibition: Phycocyanin effectively inhibited pancreatic cancer cell proliferation in a concentration-dependent manner
• Cell cycle arrest: Phycocyanin induced G2/M cell cycle arrest, preventing cancer cells from dividing
• Dual cell death pathways: Phycocyanin triggered both apoptosis (programmed cell death) and autophagy (cellular self-digestion) in PANC-1 cells
• Selective toxicity: The compound showed significantly less toxicity toward normal cells compared to cancer cells

In Vivo Results (Animal Studies)

Critically, phycocyanin didn’t just work in a petri dish — it also inhibited xenograft tumor growth in vivo (in living animals). This is a crucial validation step, showing that the anticancer effects observed in cell cultures translate to actual tumor reduction in a whole organism.

Molecular Pathways Identified

The study mapped out the precise molecular mechanisms through which phycocyanin kills pancreatic cancer cells:

• MAPK pathway modulation: Phycocyanin activates p38 and JNK signaling (pro-apoptotic) while inhibiting the Erk pathway (pro-survival)
• PI3K/Akt/mTOR inhibition: By suppressing this key survival pathway, phycocyanin promotes autophagic cell death — the cancer cell essentially digests itself
• NF-κB activation and nuclear translocation: NF-κB plays an important role in balancing phycocyanin-mediated apoptosis and autosis
• Cross-talk among pathways: The cell death is driven by coordinated signaling between MAPK, Akt/mTOR/p70S6K, and NF-κB pathways

The researchers concluded that phycocyanin is “a promising anti-pancreatic cancer agent” based on its ability to induce both apoptotic and autophagic cell death through multiple pathways.

Reference: Liao et al., Scientific Reports, 2016.

---

2026 Breakthrough: Spirulina Polysaccharide Targets Pancreatic Cancer

In one of the newest studies on spirulina and pancreatic cancer, published in the Chinese Journal of Natural Medicines in February 2026, researchers identified a previously unknown spirulina polysaccharide with potent anti-pancreatic cancer activity.

The Discovery: ESPPW

The researchers isolated a homogeneous polysaccharide called ESPPW from Arthrospira platensis (spirulina). With a molecular weight of approximately 356 kDa, ESPPW consists predominantly of glucose and rhamnose, with trace amounts of mannose, glucuronic acid, and other sugars.

Anti-Pancreatic Cancer Effects

ESPPW demonstrated significant anti-PDAC activity:

• Inhibited proliferation of PDAC cells both in vitro and in vivo
• Inhibited migration — reducing the ability of pancreatic cancer cells to spread
• Induced apoptosis through activation of caspase-3 and upregulation of tumor suppressor p53

Novel Mechanism: Galectin-3 and Glypican-6

What makes this study particularly exciting is the identification of a novel mechanism of action. ESPPW caused significant downregulation of two proteins that promote cancer progression:

• Galectin-3 (Gal-3): A protein involved in cancer cell adhesion, proliferation, and metastasis
• Glypican-6 (GPC-6): A cell surface proteoglycan linked to tumor growth signaling

When researchers overexpressed Gal-3 and GPC-6 in cancer cells, it reversed the pro-apoptotic effect of ESPPW — confirming that these proteins are direct targets of the spirulina polysaccharide. These findings were validated by immunohistochemical analysis of tumor xenograft tissues.

This study is significant because it shows that spirulina’s anticancer effects against pancreatic cancer extend beyond phycocyanin to include polysaccharide compounds with distinct mechanisms of action.

Reference: Heriniaina et al., Chinese Journal of Natural Medicines, 2026.

---

Spirulina-Derived Photodynamic Therapy for Pancreatic Cancer

A unique application of spirulina in pancreatic cancer treatment comes from photodynamic therapy (PDT) research. In 2018, researchers at Xinhua Hospital (Shanghai Jiao Tong University) tested YLG-1 — a novel photosensitizer extracted from spirulina — for pancreatic cancer PDT.

How It Works

YLG-1 localizes to the mitochondria of cancer cells. When activated by 650 nm light irradiation, it generates reactive oxygen species (ROS) that destroy cancer cells from within. The optimal protocol involved intratumoral injection followed by light activation 2 hours later.

Results

• Potent cytotoxic effect on pancreatic cancer cells under light irradiation
• Cancer cell death occurred through apoptosis, with upregulated Bax and cleaved Caspase-3 and decreased Bcl-2
• Significant tumor growth inhibition in a mouse model of subcutaneous pancreatic tumors
• The ROS scavenger NAC abolished the effect, confirming ROS-mediated killing

While photodynamic therapy for pancreatic cancer is still experimental, this spirulina-derived approach represents a novel treatment avenue that could complement conventional therapies.

Reference: Shen et al., World Journal of Gastroenterology, 2018.

---

Spirulina as Chemotherapy Support: Protecting Patients During Treatment

Beyond direct anticancer effects, spirulina shows promise as a supportive therapy during pancreatic cancer chemotherapy. Two important clinical studies address this:

Spirulina Reduces Myelosuppression During Chemotherapy (Ge et al., 2019)

In a randomized controlled trial at Beijing Chao-Yang Hospital, 100 cancer patients undergoing chemotherapy were randomized to receive spirulina supplementation (n=60) or standard care (n=40). The results showed:

• Significantly higher white blood cell and neutrophil counts in the spirulina group after cycles 1 and 2
• Lower rate of severe myelosuppression (p=0.034)
• Less need to modify chemotherapy regimens (p=0.012) — meaning patients could stay on their full treatment schedule
• Improved immune function: IgM levels and CD8+ T cell counts increased in the spirulina group but decreased in controls

This is particularly relevant for pancreatic cancer patients, who frequently receive aggressive chemotherapy regimens like FOLFIRINOX or gemcitabine/nab-paclitaxel that cause significant myelosuppression.

PROPERTY Trial: Phycocyanin for Neuroprotection During GI Cancer Chemo (Ongoing)

The PROPERTY trial (NCT05025826) is a randomized, double-blind, placebo-controlled multicenter study across seven French hospitals testing PHYCOCARE® — a standardized phycocyanin product — for preventing oxaliplatin-induced peripheral neuropathy. The trial includes 110 patients with metastatic gastrointestinal cancers, including pancreatic cancer patients.

Chemotherapy-induced peripheral neuropathy (CIPN) affects 19-85% of cancer patients and currently has no effective prevention. If the PROPERTY trial confirms phycocyanin’s neuroprotective effects, it would add a significant quality-of-life benefit for pancreatic cancer patients undergoing oxaliplatin-based treatment.

For a complete review of spirulina during cancer treatment, see our guide on spirulina during chemotherapy.

---

How Spirulina Works Against Pancreatic Cancer: The Mechanisms

The research reveals that spirulina targets pancreatic cancer through at least five distinct mechanisms:

1. Direct Cancer Cell Killing Through Apoptosis

Phycocyanin activates pro-apoptotic proteins (Bax, p53, cleaved Caspase-3) while suppressing anti-apoptotic proteins (Bcl-2). This shifts the cellular balance toward programmed cell death. The MAPK pathway modulation — activating p38/JNK while inhibiting Erk — is central to this process.

2. Autophagic Cell Death

Uniquely among natural compounds, phycocyanin also triggers autophagy in pancreatic cancer cells by inhibiting the PI3K/Akt/mTOR pathway. This represents a second, independent pathway of cell death — making it harder for cancer cells to develop resistance.

3. Anti-Metastatic Activity

The 2026 ESPPW polysaccharide study demonstrated that spirulina compounds can inhibit pancreatic cancer cell migration — a critical step in metastasis. By targeting Galectin-3 and Glypican-6, spirulina polysaccharides may help prevent the spread of PDAC to other organs.

4. Anti-Inflammatory Protection

Chronic pancreatitis is a known risk factor for pancreatic cancer, and inflammation drives disease progression. Phycocyanin is a potent inhibitor of NF-κB and COX-2 — key inflammatory mediators. This anti-inflammatory action may both reduce cancer risk and slow tumor progression. Learn more about spirulina’s anti-inflammatory effects.

5. Immune System Enhancement

Pancreatic cancer creates an immunosuppressive tumor microenvironment. Spirulina boosts natural killer (NK) cell activity, enhances macrophage function, and — as the Ge et al. clinical trial showed — protects immune cells during chemotherapy. The K-001 Phase I trial also measured regulatory T cell (Treg) changes as a secondary endpoint, reflecting the importance of immune modulation in PDAC treatment. For the complete overview, see our guide on spirulina health benefits.

---

Dosage, Safety, and How to Use Spirulina for Pancreatic Cancer Support

Recommended Dosage Based on Research

For General Cancer Prevention:

• Maintenance dose: 3-5 grams of spirulina daily
• Duration: Ongoing daily supplementation
• Individuals with chronic pancreatitis or family history of pancreatic cancer may particularly benefit

For Active Cancer Support (During Treatment):

• Therapeutic dose: 5-10 grams daily, divided into 2-3 doses with meals
• K-001 trial doses: ranged from 2,700 to 4,320 mg/day of the formulated extract, all well tolerated
• Timing: Coordinate with your oncologist relative to chemotherapy sessions
• Duration: Throughout treatment and recovery period

For Chemotherapy Support (Myelosuppression/Immune Protection):

• Dose: Based on the Ge et al. clinical trial protocol
• Begin supplementation before starting chemotherapy if possible
• Continue throughout treatment cycles

For detailed dosage guidance across all cancer types, see our comprehensive spirulina and cancer guide.

Safety Profile

Spirulina has demonstrated an excellent safety record across all clinical studies:

• The K-001 Phase I trial found no grade 3 or 4 drug-related adverse events even at the highest dose
• The most common side effects were mild digestive issues (dyspepsia, flatulence)
• The Ge et al. chemotherapy trial reported no adverse effects from spirulina supplementation
• Those with autoimmune conditions should consult their physician due to spirulina’s immune-stimulating properties
• Individuals with PKU (phenylketonuria) should avoid spirulina due to phenylalanine content

Who Should Consider Spirulina for Pancreatic Cancer Support?

• Patients with diagnosed PDAC exploring complementary approaches alongside standard treatment
• Those with chronic pancreatitis — a known risk factor for pancreatic cancer
• Individuals with a family history of pancreatic cancer
• Patients undergoing chemotherapy who want to support immune function and reduce myelosuppression
• People with diabetes (type 2 diabetes is associated with increased pancreatic cancer risk)

---

Why Spirulina Quality Matters for Cancer Research Applications

For therapeutic applications like pancreatic cancer support, the quality of your spirulina directly impacts its potential efficacy. The key active compounds — phycocyanin and polysaccharides — are both sensitive to heat and processing methods.

Freeze-Dried vs. Spray-Dried: A Critical Difference

Most commercial spirulina is spray-dried using temperatures of 150-200°F, which degrades a significant portion of the phycocyanin and can alter polysaccharide structures. Freeze-dried spirulina preserves these heat-sensitive compounds by removing moisture at sub-zero temperatures.

The 2016 Liao et al. study and the 2026 Heriniaina et al. study both used carefully extracted, high-purity compounds from spirulina. For consumers seeking similar benefits, maximizing phycocyanin and polysaccharide content through quality sourcing is essential.

Royal Spirulina is freeze-dried, USA-grown, and independently rated #1 by Goodnature.com with a perfect 10/10 score. For cancer support applications, this higher preservation of bioactive compounds matters.

To learn more about choosing the best spirulina powder, see our comprehensive quality comparison guide.

→ Shop Royal Spirulina Now

---

Frequently Asked Questions

Has spirulina been tested in human clinical trials for pancreatic cancer?

Yes. A Phase I clinical trial (NCT02720666) at Shanghai General Hospital tested K-001, an oral drug derived from spirulina’s active ingredients, in 12 patients with advanced pancreatic ductal adenocarcinoma. The trial showed an 83.3% disease control rate with no serious adverse events. The researchers recommended Phase II/III evaluation.

How does phycocyanin kill pancreatic cancer cells?

Phycocyanin triggers two independent cell death pathways in pancreatic cancer cells: apoptosis (via MAPK pathway activation of p38/JNK and Erk inhibition) and autophagy (via PI3K/Akt/mTOR pathway inhibition). This dual mechanism makes it harder for cancer cells to develop resistance. Importantly, phycocyanin shows selective toxicity — killing cancer cells while largely sparing normal cells.

Can spirulina help during pancreatic cancer chemotherapy?

Clinical evidence suggests yes. A randomized controlled trial showed that spirulina supplementation during chemotherapy significantly reduced myelosuppression, preserved immune function (white blood cells, neutrophils, CD8+ T cells, IgM), and decreased the need for chemotherapy regimen modifications. Additionally, the PROPERTY trial is evaluating phycocyanin for preventing chemotherapy-induced neuropathy in gastrointestinal cancer patients.

What is the recommended spirulina dosage for pancreatic cancer support?

For general cancer prevention, 3-5 grams daily is commonly recommended. For active cancer support alongside treatment, 5-10 grams daily (divided into 2-3 doses) may be appropriate. The K-001 clinical trial used 2,700-4,320 mg/day of a formulated spirulina extract, all doses of which were well tolerated. Always consult your oncologist before adding supplements to your cancer treatment plan.

Is spirulina safe for pancreatic cancer patients?

The K-001 Phase I trial specifically demonstrated excellent safety in advanced PDAC patients, with no dose-limiting toxicity and no grade 3-4 adverse events. The most common side effects were mild digestive symptoms. However, pancreatic cancer patients should always discuss supplement use with their treatment team, especially when undergoing chemotherapy.

What is the new 2026 spirulina polysaccharide research?

A February 2026 study identified a spirulina polysaccharide called ESPPW that inhibits pancreatic cancer cell proliferation and migration by targeting Galectin-3 and Glypican-6 — two proteins involved in tumor progression. This shows that spirulina’s anticancer effects extend beyond phycocyanin to include polysaccharide compounds with distinct mechanisms.

---

More Spirulina Cancer Research

• Spirulina and Cancer: What 50+ Research Studies Show (2026 Guide)
• Phycocyanin and Cancer: Scientific Evidence
• Spirulina and Oral Cancer: The Human Clinical Trial
• Spirulina and Breast Cancer Research
• Spirulina and Lung Cancer Research
• Spirulina and Colon Cancer Research
• Spirulina During Chemotherapy: Clinical Trial Results
• Spirulina Health Benefits: 8 Science-Backed Reasons
• Best Spirulina Powder Guide

---

The Strongest Evidence for Any Spirulina-Derived Drug in Pancreatic Cancer

Pancreatic cancer remains one of medicine’s greatest challenges, but the research on spirulina-derived compounds offers genuine hope. The K-001 Phase I trial — achieving 83.3% disease control with no serious toxicity in advanced PDAC patients — represents the first human evidence that a spirulina-derived agent has meaningful activity against this devastating disease. Combined with the laboratory evidence showing phycocyanin kills pancreatic cancer cells through dual apoptotic/autophagic pathways, the new 2026 polysaccharide research targeting novel molecular mechanisms, and the clinical evidence for spirulina protecting patients during chemotherapy, the case for spirulina in pancreatic cancer research continues to build.

Further Phase II and III clinical trials are needed, but the safety profile and preliminary efficacy data make spirulina-derived compounds a promising area of ongoing investigation for one of the hardest-to-treat cancers.

Important disclaimer: This article is for educational purposes only and is not intended as medical advice. Spirulina is not a treatment, cure, or replacement for conventional pancreatic cancer therapy. Always consult your oncologist or healthcare provider for personalized medical guidance.

Explore Royal Spirulina Products →